Structure-based classification predicts drug response in EGFR-mutant NSCLC.

doi:10.1038/s41586-021-03898-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Structure-based classification predicts drug response in EGFR-mutant NSCLC.

Nature - 1 Sept 2021

Robichaux Jacqulyne P, Le Xiuning, Vijayan R S K, Hicks J Kevin, Heeke Simon, Elamin Yasir Y, Lin Heather Y, Udagawa Hibiki, Skoulidis Ferdinandos, Tran Hai, Varghese Susan, He Junqin, Zhang Fahao, Nilsson Monique B, Hu Lemei, Poteete Alissa, Rinsurongkawong Waree, Zhang Xiaoshan, Ren Chenghui, Liu Xiaoke, Hong Lingzhi, Zhang Jianjun, Diao Lixia, Madison Russell, Schrock Alexa B, Saam Jennifer, Raymond Victoria, Fang Bingliang, Wang Jing, Ha Min Jin, Cross Jason B, Gray Jhanelle E, Heymach John V

Abstract excerpt

Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18-21 and are established driver mutations in non-small cell lung cancer (NSCLC)1-3. Targeted therapies are approved for patients with 'classical' mutations and a small number of other mutations4-6. However, effective therapies have not been identified for additional EGFR mutations. Furthermore, the frequency and effects of atypical EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Docking Simulation

Share to Afatinib

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Repositioning

Share to Drug Resistance, Neoplasm

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 34526717
DOI: 10.1038/s41586-021-03898-1
PMCID: PMC8481125

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure-based classification predicts drug response in EGFR-mutant NSCLC.PMID 34526717Read ↗

Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC.Semantic proximity Read ↗

Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy.Semantic proximity Read ↗

Atypical EGFR Mutations Show Heterogeneity.Semantic proximity Read ↗

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function AnalysisSemantic proximity Read ↗

Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): 'Where the streets have no name'.Semantic proximity Read ↗

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Semantic proximity Read ↗

The next tier of EGFR resistance mutations in lung cancer.Semantic proximity Read ↗

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World StudySemantic proximity Read ↗

Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancer.Semantic proximity Read ↗

Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistanceSemantic proximity Read ↗

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.